Nektar Therapeutics (NKTR)

Market Cap	260.74M
Revenue (ttm)	90.12M
Net Income (ttm)	-276.06M
Shares Out	183.62M
EPS (ttm)	-1.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,100,016
Open	1.390
Previous Close	1.360
Day's Range	1.310 - 1.430
52-Week Range	0.410 - 1.750
Beta	0.91
Analysts	Hold
Price Target	3.50 (+146.48%)
Earnings Date	May 7, 2024

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 137
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR

Financial Performance

In 2023, NKTR's revenue was $90.12 million, a decrease of -2.10% compared to the previous year's $92.06 million. Losses were -$276.06 million, -25.03% less than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for NKTR stock is "Hold." The 12-month stock price forecast is $3.5, which is an increase of 146.48% from the latest price.

Price Target

$3.5

(146.48% upside)

Analyst Consensus: Hold